Collaborative Efforts and Reports. The parties agree that the successful execution of the Alliance Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the Alliance Steering Committee fully informed about the status of the portions of the Alliance Program they respectively perform separately and/or jointly. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 406 of the Securities Act.
Collaborative Efforts and Reports. (a) The parties agree that the successful execution of the R&D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the RDSC fully informed about the status of the portions of the R&D Program they respectively perform. Without limiting the foregoing, each party shall furnish to the RDSC quarterly written reports within 30 days after the end of each quarterly period, describing the progress of its activities in connection with the R&D Program in reasonable detail, including: (i) a detailed accounting of the FTEs used, (ii) a reasonably detailed synopsis of the screening and testing of Gene Variants and Shuffled Genes, and the development of Shuffled Genes and PIONEER Licensed Products, and (iii) a description of Intellectual Property arising from the R&D Program. It is understood and agreed that reports regarding the development and commercialization of PIONEER Licensed Products outside the scope of the R&D Program shall be subject to (P)5.3 below, and that reports regarding the development and commercialization of MAXYGEN Licensed Products outside the scope of the R&D Program shall be subject to (P)5.4 below.
Collaborative Efforts and Reports. The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties’ areas of expertise. The Parties shall keep the JDC and each other fully informed about the status of the Research Program. Scientists at ImmunoGen and Bayer shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to Third Parties, shall exchange information and materials in a mutually acceptable secure manner as necessary to carry out the Research Program, subject to the provisions of Section 6 hereof.
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties' areas of expertise. Each Party shall keep the RC fully informed about the status of the portions of the Research Program they respectively perform including, without limitation, summaries of their direct uses of the Project Data itself for so long as GENENTECH shall have an option to license such Project Data hereunder. CURAGEN shall promptly provide GENENTECH with a description of Project Data Sets from completed Research Projects. All information provided hereunder will be treated as Confidential Information of the disclosing Party pursuant to the provisions of Article 4.
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties' areas of expertise. The Parties shall keep the RC fully informed about the status of the portions of the Research Program they respectively perform. In particular, without limitation, each Party shall furnish to the RC quarterly written reports within thirty (30) days after the end of each quarterly period, describing the progress of its activities in reasonable detail, including (x) a summary of Project Data from ongoing Research Projects, (y) a summary of uses of Project Data and (z) a description of Project Data Sets from [Confidential Treatment Requested]
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the R&D Program will require the collaborative use of both Parties' areas of expertise. The Parties shall keep the RMC fully informed about the status of the portions of the R&D Program they respectively perform. Without limiting the foregoing, each Party shall furnish to the RMC [*****] reports within [*****] days after the end of each [*****] period, describing the progress of its activities in connection with the R&D Program in reasonable 8 * Confidential Treatment Requested detail, including at least:
Collaborative Efforts and Reports. The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties’ areas of expertise. The Parties shall keep the Collaboration Committee and each other fully informed about the status of the Research Program. Scientists at ImmunoGen and Biogen Idec shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to Third Parties, shall exchange information and materials in a mutually acceptable secure manner as necessary to carry out the Research Program, but subject to the provisions of Section 6 hereof. The Parties expect that such exchange of information and materials may involve short-term on-site visits (up to a few weeks) by scientists of each Party to the facilities of the other Party.
Collaborative Efforts and Reports. (d) The parties agree that the successful execution of the R&D Program will require the collaborative use of both parties’ areas of expertise. The parties shall keep the RSC fully informed about the status of the portions of the R&D Program they respectively perform. In particular, without limitation, SEMBIOSYS shall furnish to the RSC quarterly written reports within thirty (30) days after the end of each Calendar Quarter, describing the progress of its activities in reasonable detail, including a description of Program Intellectual Property arising from SEMBIOSYS’ research efforts and accomplishments.
Collaborative Efforts and Reports. (a) The parties agree that the successful execution of the R&D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the RDSC fully informed about the status of the portions of the R&D Program they respectively perform. In particular, without limitation, each party shall furnish to the RDSC and each other semi-annual written reports within thirty (30) days after the end of each semi-annual period, describing the progress of its activities in reasonable detail, including (x) a detailed accounting of the FTEs used and actual allocation of FTEs, and (y) a description of Proprietary Intellectual Property arising 10 [Confidential Treatment Requested] from (i) CURAGEN's research efforts and accomplishments and (ii) PIONEER's research programs, breeding programs and field tests. The RDSC shall also be kept informed of any efforts by PIONEER or the parties jointly to (x) pursue commercialization partners in the PIONEER Commercialization Field or (y) pursue research partners for the purpose of facilitating additional research within the R&D Field beyond the scope of the research on Target Traits described in the Work Plan. Any such expansion of the research efforts in the R&D Field shall include additional research funding for CURAGEN and may include additional payments to the parties in the form of additional up front fees, milestone fees, royalties or license fees which shall be shared by the parties in a mutually agreeable manner so as to reflect each party's contribution to any such expanded collaboration.
Collaborative Efforts and Reports. The parties agree that the successful execution of the R & D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the JSC and each other fully informed about the status of the portions of the R & D Program they respectively perform. In particular, without limitation, each party shall furnish to the JSC and each other a quarterly written report, describing the progress of its activities in reasonable detail, no later than thirty (30) days after the end of each Fiscal Quarter. Scientists at CHEMGENICS and WYETH-AYERST shall cooperate in the performance of the R & D Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the R & D Program, but subject to the provisions of Sections 4 and 5 hereof. Each party will attempt to accommodate any reasonable request of the other party to send or receive personnel for purposes of collaborating or exchanging information under the R & D Program. Such visits and/or access will have defined purposes and be scheduled in advance. The requesting party will bear the travel and lodging costs of any such personnel.
